$TYRA
Tyra Biosciences, Inc. Stock $tyra

$tyra Overview Financials Valuation SEC Filings Company Website

2022 Q1 Form 10-K Financial Statement

#000095017022002814 Filed on March 03, 2022

Income Statement

Concept	2022 Q1	2021 Q4	2021
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$5.189M	$2.682M	$5.652M
YoY Change	653.12%	28.08%	169.91%
% of Gross Profit
Research & Development	$9.645M	$7.250M	$20.64M
YoY Change	173.85%	147.44%	186.49%
% of Gross Profit
Depreciation & Amortization	$64.00K	$50.00K	$140.0K
YoY Change	190.91%	163.16%	197.87%
% of Gross Profit
Operating Expenses	$14.83M	$9.932M	$26.29M
YoY Change	252.27%	6.83%	182.76%
Operating Profit	-$14.83M		-$26.29M
YoY Change	252.27%		182.76%
Interest Expense	$18.00K	$5.000K	$13.00K
YoY Change	800.0%	-600.0%	-750.0%
% of Operating Profit
Other Income/Expense, Net	$8.000K	-$3.000K	-$6.000K
YoY Change	300.0%	-92.11%	-84.62%
Pretax Income	-$14.83M	-$9.930M	-$26.29M
YoY Change	252.25%	6.36%	181.64%
Income Tax			$1.000K
% Of Pretax Income
Net Earnings	-$14.83M	-$9.930M	-$26.29M
YoY Change	252.25%	169.47%	181.64%
Net Earnings / Revenue
Basic Earnings Per Share	-$0.36		-$1.91
Diluted Earnings Per Share	-$356.8K	-$219.2K	-$634.5K
COMMON SHARES
Basic Shares Outstanding	41.60M	41.27M	13.78M
Diluted Shares Outstanding	41.55M		13.78M

Balance Sheet

Concept	2022 Q1	2021 Q4	2021
SHORT-TERM ASSETS
Cash & Short-Term Investments	$292.5M	$302.2M	$302.2M
YoY Change	107.98%		1884.91%
Cash & Equivalents	$292.5M	$302.2M	$302.2M
Short-Term Investments
Other Short-Term Assets	$1.526M	$1.875M	$1.875M
YoY Change	703.16%		3189.47%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$294.0M	$304.1M	$304.1M
YoY Change	108.78%	1889.77%	1889.77%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.008M	$1.027M	$2.089M
YoY Change	115.85%	245.79%	348.28%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$362.0K	$312.0K	$555.0K
YoY Change	-29.57%	1385.71%	110.23%
Total Long-Term Assets	$4.946M	$2.644M	$2.644M
YoY Change	404.18%	262.19%	262.19%
TOTAL ASSETS
Total Short-Term Assets	$294.0M	$304.1M	$304.1M
Total Long-Term Assets	$4.946M	$2.644M	$2.644M
Total Assets	$299.0M	$306.7M	$306.7M
YoY Change	110.83%	1815.56%	1815.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$1.356M	$599.0K	$599.0K
YoY Change	61.24%	-9.79%	-9.79%
Accrued Expenses	$3.545M	$3.017M	$3.017M
YoY Change	410.81%		154.6%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$4.901M	$3.616M	$3.616M
YoY Change	219.28%	94.62%	94.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$303.0K	$367.0K	$1.348M
YoY Change	-41.95%	162.14%	862.86%
Total Long-Term Liabilities	$303.0K	$367.0K	$1.348M
YoY Change	-41.95%	162.14%	862.86%
TOTAL LIABILITIES
Total Short-Term Liabilities	$4.901M	$3.616M	$3.616M
Total Long-Term Liabilities	$303.0K	$367.0K	$1.348M
Total Liabilities	$7.787M	$4.964M	$4.964M
YoY Change	278.56%	148.45%	148.45%
SHAREHOLDERS EQUITY
Retained Earnings	-$55.20M	-$40.37M
YoY Change		186.79%
Common Stock	$346.4M	$342.1M
YoY Change		77828.93%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$291.2M	$301.7M	$301.7M
YoY Change
Total Liabilities & Shareholders Equity	$299.0M	$306.7M	$306.7M
YoY Change	110.83%	1815.56%	1815.56%

Cashflow Statement

Concept	2022 Q1	2021 Q4	2021
OPERATING ACTIVITIES
Net Income	-$14.83M	-$9.930M	-$26.29M
YoY Change	252.25%	169.47%	181.64%
Depreciation, Depletion And Amortization	$64.00K	$50.00K	$140.0K
YoY Change	190.91%	163.16%	197.87%
Cash From Operating Activities	-$8.925M	-$9.028M	-$23.75M
YoY Change	90.79%	256.84%	205.87%
INVESTING ACTIVITIES
Capital Expenditures	$239.0K	-$105.0K	$661.0K
YoY Change	298.33%	56.72%	111.86%
Acquisitions
YoY Change
Other Investing Activities		$0.00	$16.00K
YoY Change
Cash From Investing Activities	-$239.0K	-$105.0K	-$645.0K
YoY Change	298.33%	56.72%	106.73%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	238.0K	-1.508M	311.3M
YoY Change	-99.82%	37600.0%	1228.62%
NET CHANGE
Cash From Operating Activities	-8.925M	-9.028M	-23.75M
Cash From Investing Activities	-239.0K	-105.0K	-645.0K
Cash From Financing Activities	238.0K	-1.508M	311.3M
Net Change In Cash	-8.926M	-10.64M	287.0M
YoY Change	-107.12%	309.11%	1768.34%
FREE CASH FLOW
Cash From Operating Activities	-$8.925M	-$9.028M	-$23.75M
Capital Expenditures	$239.0K	-$105.0K	$661.0K
Free Cash Flow	-$9.164M	-$8.923M	-$24.41M
YoY Change	93.41%	262.28%	202.24%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2021	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021	dei	Amendment Flag AmendmentFlag	false
CY2021	dei	Entity Address Address Line1 EntityAddressAddressLine1	2656 State Street
CY2021	dei	Entity Address City Or Town EntityAddressCityOrTown	Carlsbad
CY2021	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92008
CY2021	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	83-1476348
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2021	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2021	dei	Entity Central Index Key EntityCentralIndexKey	0001863127
CY2021	dei	Document Type DocumentType	10-K
CY2021	dei	Document Annual Report DocumentAnnualReport	true
CY2021	dei	Document Period End Date DocumentPeriodEndDate	2021-12-31
CY2021	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021	dei	Document Transition Report DocumentTransitionReport	false
CY2021	dei	Entity File Number EntityFileNumber	001-40800
CY2021	dei	Entity Registrant Name EntityRegistrantName	TYRA BIOSCIENCES, INC.
CY2021	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021	dei	City Area Code CityAreaCode	619
CY2021	dei	Local Phone Number LocalPhoneNumber	728-4760
CY2021	dei	Security12b Title Security12bTitle	Common Stock, $0.0001 par value per share
CY2021	dei	Trading Symbol TradingSymbol	TYRA
CY2021	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2021	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2021	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021	dei	Entity Small Business EntitySmallBusiness	true
CY2021	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2021	dei	Entity Shell Company EntityShellCompany	false
CY2021Q3	dei	Entity Public Float EntityPublicFloat	299000000.0
CY2022Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	41604514
CY2021	dei	Auditor Name AuditorName	Ernst & Young LLP
CY2021	dei	Auditor Location AuditorLocation	San Diego, California
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	302182000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15224000
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1875000
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	57000
CY2021Q4	us-gaap	Assets Current AssetsCurrent	304057000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	15281000
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	243000
CY2020Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	243000
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1027000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	297000
CY2021Q4	tyra	Right Of Use Asset RightOfUseAsset	1062000
CY2020Q4	tyra	Right Of Use Asset RightOfUseAsset	169000
CY2021Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	312000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	21000
CY2021Q4	us-gaap	Assets Assets	306701000
CY2020Q4	us-gaap	Assets Assets	16011000
CY2021Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	47000
CY2020Q4	us-gaap	Accounts Payable Related Parties Current AccountsPayableRelatedPartiesCurrent	0
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	599000
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	664000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	202000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	142000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2815000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1052000
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	3616000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	1858000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	981000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	0
CY2021Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	367000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	140000
CY2021Q4	us-gaap	Liabilities Liabilities	4964000
CY2020Q4	us-gaap	Liabilities Liabilities	1998000
CY2021Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	0
CY2020Q4	us-gaap	Temporary Equity Carrying Amount Attributable To Parent TemporaryEquityCarryingAmountAttributableToParent	27651000
CY2021Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	50000000
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	0
CY2021Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2021Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2021Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	500000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	42536183
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	3050781
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	41441135
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	1829377
CY2021	us-gaap	Operating Expenses OperatingExpenses	26288000
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	20636000
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7203000
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	4000
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	0
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	342104000
CY2020Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	439000
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40371000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-14077000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	301737000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-13638000
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	306701000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	16011000
CY2021	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	435000
CY2020	us-gaap	Related Party Transaction Selling General And Administrative Expenses From Transactions With Related Party RelatedPartyTransactionSellingGeneralAndAdministrativeExpensesFromTransactionsWithRelatedParty	0
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5652000
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2094000
CY2020	us-gaap	Operating Expenses OperatingExpenses	9297000
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-26288000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-9297000
CY2021	tyra	Investment Income Interest Expense InvestmentIncomeInterestExpense	13000
CY2020	tyra	Investment Income Interest Expense InvestmentIncomeInterestExpense	-1000
CY2021	tyra	Fair Value Adjustment Of Commitments FairValueAdjustmentOfCommitments	0
CY2020	tyra	Fair Value Adjustment Of Commitments FairValueAdjustmentOfCommitments	15000
CY2021	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	19000
CY2020	us-gaap	Other Nonoperating Expense OtherNonoperatingExpense	23000
CY2021	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-6000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-39000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26294000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-9336000
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.91
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.05
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13780546
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1542174
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-4741000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	439000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-9336000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-13638000
CY2021	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	157274000
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	181220000
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	89000
CY2021	tyra	Vesting Of Shares Of Common Stock Subject To Repurchase VestingOfSharesOfCommonStockSubjectToRepurchase	199000
CY2021	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2887000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26294000
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	301737000
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26294000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-9336000
CY2021	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	140000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	47000
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2887000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	439000
CY2021	tyra	Fair Value Adjustment Of Commitments FairValueAdjustmentOfCommitments	0
CY2020	tyra	Fair Value Adjustment Of Commitments FairValueAdjustmentOfCommitments	15000
CY2021	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-3000
CY2020	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-2000
CY2021	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	2108000
CY2020	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	-65000
CY2021	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1492000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1019000
CY2021	tyra	Increase Decrease In Right Of Use Assets And Lease Liabilities Net IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet	135000
CY2020	tyra	Increase Decrease In Right Of Use Assets And Lease Liabilities Net IncreaseDecreaseInRightOfUseAssetsAndLeaseLiabilitiesNet	-14000
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-23745000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-7763000
CY2021	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	661000
CY2020	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	140000
CY2021	us-gaap	Early Repayment Of Subordinated Debt EarlyRepaymentOfSubordinatedDebt	25000
CY2020	us-gaap	Early Repayment Of Subordinated Debt EarlyRepaymentOfSubordinatedDebt	0
CY2021	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	9000
CY2020	us-gaap	Finance Lease Principal Payments FinanceLeasePrincipalPayments	17000
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	311348000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	23434000
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	286958000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	15359000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15467000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	108000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	302425000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15467000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	302182000
CY2020	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	312000
CY2021	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	16000
CY2020	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	0
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-645000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-312000
CY2021	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	181220000
CY2020	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	0
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	89000
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	0
CY2021	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	450000
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	15224000
CY2021Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	243000
CY2020Q4	us-gaap	Restricted Cash And Cash Equivalents RestrictedCashAndCashEquivalents	243000
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	302425000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15467000
CY2021	us-gaap	Interest Paid Net InterestPaidNet	0
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1000
CY2021	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	1238000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	101000
CY2021	tyra	Conversion Of Convertible Preferred Stock In Connection With Initial Public Offering ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering	157274000
CY2020	tyra	Conversion Of Convertible Preferred Stock In Connection With Initial Public Offering ConversionOfConvertiblePreferredStockInConnectionWithInitialPublicOffering	0
CY2021	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	209000
CY2020	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	4000
CY2021	tyra	Issuance Of Convertible Preferred Stock In Exchange For Simple Agreement For Future Equity IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity	0
CY2020	tyra	Issuance Of Convertible Preferred Stock In Exchange For Simple Agreement For Future Equity IssuanceOfConvertiblePreferredStockInExchangeForSimpleAgreementForFutureEquity	4340000
CY2021	dei	Entity Incorporation Date Of Incorporation EntityIncorporationDateOfIncorporation	2018-08-02
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-40400000
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	302200000
CY2021Q3	us-gaap	Stockholders Equity Note Stock Split Conversion Ratio1 StockholdersEquityNoteStockSplitConversionRatio1	0.025974
CY2021Q3	tyra	Increase In Authorized Share Due To Forward Stock Split IncreaseInAuthorizedShareDueToForwardStockSplit	50000000
CY2021	us-gaap	Use Of Estimates UseOfEstimates	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Accounting estimates and management judgments reflected in the financial statements include: normal recurring accruals, including the accrual of research and development expenses; fair value of simple agreements for future equity (SAFE), common stock (prior to the Company's IPO), convertible preferred stock (prior to the Company's IPO) and stock-based compensation. Although these estimates are based on the Company’s knowledge of current events and actions it may undertake in the future, actual results may materially differ from these estimates and assumptions.</span></p>
CY2021	tyra	Dividend Yield DividendYield	0
CY2021	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:9.067%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments which potentially subject the Company to significant concentration of credit risk consist of cash and cash equivalents. The Company maintains deposits in federally insured financial institutions in excess of federally insured limits. The Company has not experienced any losses in such accounts, and management believes that the Company is not exposed to significant credit risk due to the financial position of the depository institutions in which those deposits are held.</span></p>
CY2021	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1
CY2020Q4	us-gaap	Restricted Cash RestrictedCash	200000
CY2021	us-gaap	Dividend Payment Restrictions Schedule Description DividendPaymentRestrictionsScheduleDescription	The Company has historically not declared or paid any dividends and does not currently expect to do so in the foreseeable future, and therefore has estimated the dividend yield to be zero.
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	200000
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	43000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	297000
CY2021	us-gaap	Depreciation Depreciation	140000
CY2021Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0
CY2020Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	0
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1027000
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1196000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	340000
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	169000
CY2020	us-gaap	Depreciation Depreciation	47000
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1278000
CY2020Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	774000
CY2021Q4	tyra	Accrued Research And Development AccruedResearchAndDevelopment	1257000
CY2020Q4	tyra	Accrued Research And Development AccruedResearchAndDevelopment	163000
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	61000
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	67000
CY2021Q4	tyra	Accrued Other General And Administrative Fee AccruedOtherGeneralAndAdministrativeFee	219000
CY2020Q4	tyra	Accrued Other General And Administrative Fee AccruedOtherGeneralAndAdministrativeFee	48000
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2815000
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1052000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	1374714
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.61
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y4M24D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	3287241
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	10.45
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	877855
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.62
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	285000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod	12584
CY2021	tyra	Share Based Compensation Expense Recognized Over The Requisite Service Period ShareBasedCompensationExpenseRecognizedOverTheRequisiteServicePeriod	600000
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	1.50
CY2021	tyra	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriodTotalIntrinsicValue	158000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	3771516
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.18
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y3M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	28901000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	561556
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	1.60
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P8Y4M24D
CY2021Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	7184000
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	3771516
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	9.18
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P9Y3M18D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	28901000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	2400000
CY2020	tyra	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Stock Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsStockPrice	0.61
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2887000
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	439000
CY2021Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	20200000
CY2021	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y10M24D
CY2021Q4	tyra	Provision Related To Repurchase Of Early Exercised Options ProvisionRelatedToRepurchaseOfEarlyExercisedOptions	599878
CY2020Q4	tyra	Provision Related To Repurchase Of Early Exercised Options ProvisionRelatedToRepurchaseOfEarlyExercisedOptions	230222
CY2021Q4	tyra	Liability Related To Repurchase Of Early Exercised Options LiabilityRelatedToRepurchaseOfEarlyExercisedOptions	400000
CY2020Q4	tyra	Liability Related To Repurchase Of Early Exercised Options LiabilityRelatedToRepurchaseOfEarlyExercisedOptions	100000
CY2021Q4	tyra	Common Stock Options Granted And Outstanding CommonStockOptionsGrantedAndOutstanding	3771516
CY2021Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	8535790
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-6.05
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-26294000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-9336000
CY2021	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	13780546
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	1542174
CY2021	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-1.91
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	114000
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense Other IncomeTaxReconciliationNondeductibleExpenseOther	102000
CY2021	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	680000
CY2020	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	70000
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7620000
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	1941000
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	1000
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4866564
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-5392000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-1960000
CY2021	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-1661000
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	-12000
CY2021Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	9297000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	2711000
CY2021Q4	tyra	Deferred Tax Assets Tax Credits DeferredTaxAssetsTaxCredits	874000
CY2020Q4	tyra	Deferred Tax Assets Tax Credits DeferredTaxAssetsTaxCredits	144000
CY2021Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	709000
CY2020Q4	us-gaap	Deferred Tax Assets Other DeferredTaxAssetsOther	186000
CY2021Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	10880000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	3041000
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10618000
CY2020Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	2998000
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	262000
CY2020Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	43000
CY2021Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	37000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	7000
CY2021Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	262000
CY2021Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	225000
CY2020Q4	us-gaap	Deferred Tax Liabilities Leasing Arrangements DeferredTaxLiabilitiesLeasingArrangements	36000
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	tyra	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	188000
CY2020Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet	0
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	10600000
CY2021	us-gaap	Valuation Allowance Deferred Tax Asset Change In Amount ValuationAllowanceDeferredTaxAssetChangeInAmount	7600000
CY2021	tyra	Net Operating Loss Carryforwards Available For Offsetting Against Future Taxable Income Percentage NetOperatingLossCarryforwardsAvailableForOffsettingAgainstFutureTaxableIncomePercentage	0.80
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	43000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	300000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	200000
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	200000
CY2021Q4	tyra	Net Operating Loss Carryforward NetOperatingLossCarryforward	35300000
CY2021Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0750
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	91000
CY2021Q4	us-gaap	Income Tax Examination Penalties And Interest Accrued IncomeTaxExaminationPenaltiesAndInterestAccrued	0
CY2021	tyra	Lease Expiration Year LeaseExpirationYear	2026
CY2021	tyra	Number Of Lease Term Renewal NumberOfLeaseTermRenewal	2
CY2021Q4	us-gaap	Lessee Operating Lease Renewal Term LesseeOperatingLeaseRenewalTerm	P3Y
CY2021Q4	us-gaap	Line Of Credit LineOfCredit	200000
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0750
CY2020Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	91000
CY2019Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	0
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	312000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions	91000
CY2021	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	739000
CY2020	us-gaap	Unrecognized Tax Benefits Increases Resulting From Prior Period Tax Positions UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions	0
CY2021Q4	us-gaap	Unrecognized Tax Benefits UnrecognizedTaxBenefits	1142000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	200000
CY2021	us-gaap	Operating Lease Cost OperatingLeaseCost	331000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	158000
CY2021	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	5000
CY2020	us-gaap	Finance Lease Right Of Use Asset Amortization FinanceLeaseRightOfUseAssetAmortization	9000
CY2021	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	0
CY2020	us-gaap	Finance Lease Interest Expense FinanceLeaseInterestExpense	1000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	288000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	299000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	308000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	318000
CY2020Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0750
CY2021Q4	us-gaap	Finance Lease Weighted Average Discount Rate Percent FinanceLeaseWeightedAverageDiscountRatePercent	0.0750
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	1183000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	1401000
CY2021Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	218000
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	202000
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	981000
CY2021Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y7M6D
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M18D
CY2021Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y
CY2020Q4	us-gaap	Finance Lease Weighted Average Remaining Lease Term1 FinanceLeaseWeightedAverageRemainingLeaseTerm1	P0Y7M6D
CY2021	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	0
CY2020	us-gaap	Defined Benefit Plan Contributions By Employer DefinedBenefitPlanContributionsByEmployer	0
CY2021	dei	Auditor Firm AuditorFirmId	42

Files In Submission

Name	View Source	Status
0000950170-22-002814-index-headers.html	Edgar Link	pending
0000950170-22-002814-index.html	Edgar Link	pending
0000950170-22-002814.txt	Edgar Link	pending
0000950170-22-002814-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
g312128g0303162807026.jpg	Edgar Link	pending
g312128g11a15.jpg	Edgar Link	pending
g312128g22a69.jpg	Edgar Link	pending
g312128g34a39.jpg	Edgar Link	pending
img21679349_0.jpg	Edgar Link	pending
img21679349_1.jpg	Edgar Link	pending
img21679349_10.jpg	Edgar Link	pending
img21679349_11.jpg	Edgar Link	pending
img21679349_12.jpg	Edgar Link	pending
img21679349_13.jpg	Edgar Link	pending
img21679349_14.jpg	Edgar Link	pending
img21679349_15.jpg	Edgar Link	pending
img21679349_16.jpg	Edgar Link	pending
img21679349_17.jpg	Edgar Link	pending
img21679349_18.jpg	Edgar Link	pending
img21679349_19.jpg	Edgar Link	pending
img21679349_2.jpg	Edgar Link	pending
img21679349_20.jpg	Edgar Link	pending
img21679349_21.jpg	Edgar Link	pending
img21679349_22.jpg	Edgar Link	pending
img21679349_23.jpg	Edgar Link	pending
img21679349_24.jpg	Edgar Link	pending
img21679349_25.jpg	Edgar Link	pending
img21679349_26.jpg	Edgar Link	pending
img21679349_27.jpg	Edgar Link	pending
img21679349_28.jpg	Edgar Link	pending
img21679349_3.jpg	Edgar Link	pending
img21679349_4.jpg	Edgar Link	pending
img21679349_5.jpg	Edgar Link	pending
img21679349_6.jpg	Edgar Link	pending
img21679349_7.jpg	Edgar Link	pending
img21679349_8.jpg	Edgar Link	pending
img21679349_9.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
tyra-20211231.htm	Edgar Link	pending
tyra-20211231.xsd	Edgar Link	pending
tyra-20211231_cal.xml	Edgar Link	unprocessable
tyra-20211231_def.xml	Edgar Link	unprocessable
tyra-20211231_htm.xml	Edgar Link	completed
tyra-20211231_lab.xml	Edgar Link	unprocessable
tyra-20211231_pre.xml	Edgar Link	unprocessable
tyra-ex10_12.htm	Edgar Link	pending
tyra-ex10_14.htm	Edgar Link	pending
tyra-ex10_15.htm	Edgar Link	pending
tyra-ex23_1.htm	Edgar Link	pending
tyra-ex31_1.htm	Edgar Link	pending
tyra-ex31_2.htm	Edgar Link	pending
tyra-ex32_1.htm	Edgar Link	pending
tyra-ex32_2.htm	Edgar Link	pending
tyra-ex4_3.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$TYRA
Tyra Biosciences, Inc. Stock $tyra

2022 Q1 Form 10-K Financial Statement

#000095017022002814 Filed on March 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TYRA Tyra Biosciences, Inc. Stock $tyra

2022 Q1 Form 10-K Financial Statement

#000095017022002814 Filed on March 03, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$TYRA
Tyra Biosciences, Inc. Stock $tyra